Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

NCT03345810 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT03345810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03345810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2017
Completion date
December 31, 2022
Enrollment
200 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, large cell lung carcinoma metastatic, lung adenocarcinoma metastatic, metastatic lung cancer, non small cell lung cancer